Risk factors for gastric cancer in Japan in the 2010s: a large, long-term observational study Yu TakahashiNobutake YamamichiMitsuhiro Fujishiro Original Article 24 January 2022 Pages: 481 - 489
Gastric cancer exosomes contribute to the field cancerization of gastric epithelial cells surrounding gastric cancer Jung Hwan YoonByung Joon ChoiWon Sang Park Original Article 07 January 2022 Pages: 490 - 502
CAF promotes chemoresistance through NRP2 in gastric cancer Yanpeng YangYongchen MaYucun Liu Original Article Open access 26 November 2021 Pages: 503 - 514
Crosstalk between cancer-associated fibroblasts and immune cells in peritoneal metastasis: inhibition in the migration of M2 macrophages and mast cells by Tranilast Yusuke NakamuraJun KinoshitaSachio Fushida Original Article Open access 07 January 2022 Pages: 515 - 526
LRG1 mediated by ATF3 promotes growth and angiogenesis of gastric cancer by regulating the SRC/STAT3/VEGFA pathway Lingnan HeAnqi FengMing Yang Original Article 30 January 2022 Pages: 527 - 541
Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer Lingfeng FuAtsuko YonemuraTakatsugu Ishimoto Original Article 15 February 2022 Pages: 542 - 557
Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells Shinichi UmedaMitsuro KandaYasuhiro Kodera Original Article 28 February 2022 Pages: 558 - 572
rs2671655 single nucleotide polymorphism modulates the risk for gastric cancer in Helicobacter pylori–infected individuals: a genome-wide association study in the Korean population Cheol Min ShinKyungtaek ParkDong Ho Lee Original Article 24 March 2022 Pages: 573 - 585
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS) Kohei ShitaraToshihiko DoiDavid H. Ilson Original Article Open access 08 January 2022 Pages: 586 - 597
Broad spectrum of regorafenib activity on mutant KIT and absence of clonal selection in gastrointestinal stromal tumor (GIST): correlative analysis from the GRID trial Michael JeffersChristian KappelerMichael Teufel Original Article Open access 20 January 2022 Pages: 598 - 608
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16) Bum Jun KimHee-Jung JeeDae Young Zang Original Article 11 January 2022 Pages: 609 - 618
A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer Hirotaka HasegawaKohei ShitaraYasuhiro Kodera Original Article Open access 07 March 2022 Pages: 619 - 628
Development of the PERI-Gastric (PEritoneal Recurrence Index) and PERI-Gram (Peritoneal Recurrence Index NomoGRAM) for predicting the risk of metachronous peritoneal carcinomatosis after gastrectomy with curative intent for gastric cancer Annamaria AgnesAlberto BiondiDomenico D’Ugo Original Article 22 November 2021 Pages: 629 - 639
Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials Hedde D. BiesmaTanya T. D. SoeratramNicole C. T. van Grieken Original Article Open access 07 February 2022 Pages: 640 - 651
Aspirin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma Dag HolmbergJoonas H. KauppilaJesper Lagergren Original Article Open access 15 February 2022 Pages: 652 - 658
A rare gastric lesion: diminutive, well-differentiated, Grade 3, type 3 gastric neuroendocrine tumor with extremely high ki-67 index removed en bloc under endoscopy Chunpeng ZhuHiroshi KawachiXinliang Lu Case Report 18 February 2022 Pages: 659 - 664